First patient enrolled in Biodesix and Addario Lung Cancer Medical Institute Study aiming to predict patient survival using a blood-based biomarker.
Home
2021 ASCO Annual Meeting
We are excited to be exhibiting at #ASCO21. Visit our virtual booth to learn more.
Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.
Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.
We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.